vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and MacKenzie Realty Capital, Inc. (MKZR). Click either name above to swap in a different company.
MacKenzie Realty Capital, Inc. is the larger business by last-quarter revenue ($4.6M vs $3.9M, roughly 1.2× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -42.8%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs 6.1%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
MacKenzie Realty Capital, Inc. is a U.S.-based real estate investment firm focused on acquiring, owning, and managing a diversified portfolio of income-generating commercial and residential real estate assets. It targets properties in high-growth regional markets across the U.S. to deliver consistent long-term returns to its investors.
IRD vs MKZR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.6M |
| Net Profit | — | $-4.5M |
| Gross Margin | — | — |
| Operating Margin | — | -102.5% |
| Net Margin | — | -97.4% |
| Revenue YoY | -10.2% | -42.8% |
| Net Profit YoY | 53.0% | -0.4% |
| EPS (diluted) | — | $-2.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.6M | ||
| Q3 25 | $3.1M | $4.5M | ||
| Q2 25 | $2.9M | $4.8M | ||
| Q1 25 | $4.4M | $4.3M | ||
| Q4 24 | $4.3M | $8.0M | ||
| Q3 24 | $3.9M | $5.0M | ||
| Q2 24 | $1.1M | $4.5M | ||
| Q1 24 | $1.7M | $4.1M |
| Q4 25 | — | $-4.5M | ||
| Q3 25 | $-17.5M | $-3.0M | ||
| Q2 25 | $-7.4M | $-6.0M | ||
| Q1 25 | $-8.2M | $-6.1M | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | $-7.5M | $-7.4M | ||
| Q2 24 | $-7.8M | $-2.5M | ||
| Q1 24 | $-7.1M | $-2.9M |
| Q4 25 | — | -102.5% | ||
| Q3 25 | -269.9% | -76.8% | ||
| Q2 25 | -309.0% | -117.3% | ||
| Q1 25 | -227.2% | -136.4% | ||
| Q4 24 | — | -56.7% | ||
| Q3 24 | -207.1% | -150.3% | ||
| Q2 24 | -748.9% | -58.1% | ||
| Q1 24 | -450.5% | -65.6% |
| Q4 25 | — | -97.4% | ||
| Q3 25 | -566.9% | -67.1% | ||
| Q2 25 | -257.5% | -125.1% | ||
| Q1 25 | -187.5% | -142.6% | ||
| Q4 24 | — | -55.5% | ||
| Q3 24 | -194.6% | -149.6% | ||
| Q2 24 | -698.3% | -55.6% | ||
| Q1 24 | -415.3% | -72.3% |
| Q4 25 | — | $-2.97 | ||
| Q3 25 | $-0.25 | $-2.20 | ||
| Q2 25 | $-0.12 | $-8.16 | ||
| Q1 25 | $-0.24 | $-0.47 | ||
| Q4 24 | — | $-3.93 | ||
| Q3 24 | $-0.29 | $-6.10 | ||
| Q2 24 | $-0.30 | $-9.20 | ||
| Q1 24 | $-0.29 | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $4.3M |
| Total DebtLower is stronger | — | $145.6M |
| Stockholders' EquityBook value | $15.3M | $51.8M |
| Total Assets | $50.2M | $238.1M |
| Debt / EquityLower = less leverage | — | 2.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $4.3M | ||
| Q3 25 | $30.8M | $4.9M | ||
| Q2 25 | $32.4M | $3.6M | ||
| Q1 25 | $41.8M | $5.1M | ||
| Q4 24 | $30.3M | $6.5M | ||
| Q3 24 | $36.6M | $10.7M | ||
| Q2 24 | $41.4M | $11.9M | ||
| Q1 24 | $47.2M | $15.5M |
| Q4 25 | — | $145.6M | ||
| Q3 25 | — | $142.7M | ||
| Q2 25 | — | $135.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $117.3M | ||
| Q1 24 | — | — |
| Q4 25 | $15.3M | $51.8M | ||
| Q3 25 | $6.0M | $56.7M | ||
| Q2 25 | $17.5M | $59.9M | ||
| Q1 25 | $5.1M | $66.7M | ||
| Q4 24 | $6.7M | $68.3M | ||
| Q3 24 | $34.3M | $73.4M | ||
| Q2 24 | $40.6M | $82.4M | ||
| Q1 24 | $46.1M | $86.3M |
| Q4 25 | $50.2M | $238.1M | ||
| Q3 25 | $36.1M | $241.7M | ||
| Q2 25 | $38.7M | $236.0M | ||
| Q1 25 | $48.2M | $237.1M | ||
| Q4 24 | $36.9M | $236.4M | ||
| Q3 24 | $40.4M | $243.5M | ||
| Q2 24 | $44.8M | $233.1M | ||
| Q1 24 | $51.8M | $226.1M |
| Q4 25 | — | 2.81× | ||
| Q3 25 | — | 2.52× | ||
| Q2 25 | — | 2.26× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-1.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-1.6M | ||
| Q3 25 | $-6.2M | $-2.0M | ||
| Q2 25 | $-10.3M | $-1.7M | ||
| Q1 25 | $-9.0M | $-2.6M | ||
| Q4 24 | $-25.6M | $1.9M | ||
| Q3 24 | $-5.1M | $644.4K | ||
| Q2 24 | $-7.3M | $-595.5K | ||
| Q1 24 | $-5.7M | $743.3K |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
